Abstract: A bonding structure and a power device. The bonding structure includes a first power unit and at least two bonding wires. At least one end of the bonding wire is connected to the first power unit through bonding. Projections that are of lead paths of the at least two bonding wires and that are on a preset plane have at least one intersection point. Spatial cross wire bonding is performed on the bonding wires, so that lead paths of the bonding wires form an angle with each other, thereby weakening electromagnetic force between the bonding wires. Therefore, fatigue due to fluctuating stress of the bonding wires can be alleviated, service lives of the bonding wires can be prolonged, and bonding effect can be ensured to a maximum extent.

Abstract: A packaged device includes a circuit board, an electronic component, and a heat storage portion. The electronic component is electrically coupled to the circuit board; and the heat storage portion is disposed on the circuit board or embedded in the circuit board, and the heat storage portion is adjacent to the electronic component, where a specific heat capacity of the heat storage portion is higher than a specific heat capacity of the circuit board, and the heat storage portion is configured to store and release heat. A heat storage material with a relatively high specific heat capacity is introduced into the packaged device, and the heat storage portion is disposed on the circuit board around the electronic component where a large amount of heat generated by the electronic component in a short time can be quickly stored in the heat storage portion and then released to the outside.

Abstract: Provided are a laser cutting device and a laser cutting method. The laser cutting device comprises a beam expanding element provided with a plurality of lens sets, wherein optical axes of the plurality of lens sets are located in the same line and each lens set comprises at least one lens; the beam expanding element is configured to convert an incident beam into a first beam; and a spectroscopic element arranged on a light path of an emitted light of the beam expanding element, and wherein the spectroscopic element is configured to convert the first beam into multiple second beams that are annular and spaced apart from each other.

Abstract: A processor-implemented method comprises obtaining current operational context information associated with a sensing device; obtaining an expected calibration factor parameter model associated with a patient; calculating an expected calibration factor value based on the expected calibration factor parameter model and the current operational context information; obtaining one or more electrical signals from the sensing device, the one or more electrical signals having a signal characteristic indicative of a physiological condition; converting the one or more electrical signals into a calibrated measurement value for the physiological condition using the expected calibration factor value; and outputting the calibrated measurement value for the physiological condition.

Abstract: A processor-implemented method comprises obtaining current operational context information associated with a sensing device; obtaining an expected calibration factor parameter model associated with a patient; calculating an expected calibration factor value based on the expected calibration factor parameter model and the current operational context information; obtaining one or more electrical signals from the sensing device, the one or more electrical signals having a signal characteristic indicative of a physiological condition; converting the one or more electrical signals into a calibrated measurement value for the physiological condition using the expected calibration factor value; and outputting the calibrated measurement value for the physiological condition.

Abstract: Medical devices and related patient management systems and parameter modeling methods are provided. An exemplary method of operating a sensing device associated with a patient involves obtaining current operational context information associated with the sensing device, obtaining a parameter model associated with the patient, calculating a current parameter value based on the parameter model and the current operational context information, obtaining one or more signals from a sensing element configured to measure a condition in a body of the patient, and providing an output that is influenced by the calculated current parameter value and the one or more signals.

Abstract: CNS metastases are a major cause of cancer deaths with few therapeutic options for treatment. Monoclonal anti-body-based therapy is one of the most successful therapeutic strategies for cancer; however, its efficacy is limited against CNS metastases due to insufficient CNS delivery. Here, we show significantly improved antibody delivery to the CNS using novel timed-release nanocapsules that encapsulate individual antibodies within a crosslinked phosphorylcholine polymer and gradually release cargo through hydrolysable crosslinkers. A single course of rituximab (RTX) nanocapsule treatment elevates RTX levels in the CNS by nearly 10-fold compared to native RTX. We improved control of CNS metastases in a murine xenograft model of non-Hodgkin lymphoma; moreover, using a xenograft humanized BLT mouse model, lymphomas were eliminated with a single course of RTX nanocapsule treatment. This approach is useful for treatment of cancers with CNS metastases and is generalizable for delivery of any antibody to the CNS.

Abstract: The invention disclosed herein includes nanocomplexes that are designed include enzymes that have complementary functional attributes and methods for using these nanocomplexes. Illustrative examples include nanocomplexes that comprise both an alcohol oxidase enzyme as well as a catalase enzyme. These nanocomplexes can be used in methods designed to lower blood alcohol levels in vivo, and/or to break down the toxic byproducts of alcohol metabolism. Consequently these nanocomplexes can be used to treat a variety of conditions resulting from the consumption of alcohol, including for example, acute alcohol intoxication.

Abstract: A single, optimal, fused sensor glucose value may be calculated based on respective sensor glucose values of a plurality of redundant working electrodes (WEs) of a glucose sensor. Respective electrochemical impedance spectroscopy (EIS) procedures may be performed for each of the WEs to obtain values of membrane resistance (Rmem) for each WE. A noise value and a calibration factor (CF) value may be calculated for each WE, and respective fusion weights may be calculated for Rmem, noise, and CF for each WE. An overall fusion weight may then be calculated based on the WE's Rmem fusion weight, noise fusion weight, and CF fusion weight, such that a single, optimal, fused sensor glucose value may be calculated based on the respective overall fusion weight and sensor glucose value of each of the plurality of redundant working electrodes.

Abstract: A method for intracellular delivery of single proteins or other cargo molecules by encapsulation within nanocapsules formed by interfacial polymerization of one or more types of monomers and selected protease cleavable cross-linkers is provided. The thin positively charged capsules are readily brought into the cytosol of target cells by endocytosis. The capsules are degraded by the action of endogenous proteases or co-delivered proteases on the cross-linkers releasing the functional cargo unaltered. The cross-linkers can be adapted to be cleavable by specific enzymes selected from available intracellular enzymes within the target cell or co-delivered or self-cleaving when the cargo itself is a protease. The nanocapsules produced by the methods have been shown to have long-term stability, high cell penetration capability, low toxicity and efficient protease-modulated specific degradability without affecting cargo protein function.

Abstract: A single, optimal, fused sensor glucose value may be calculated based on respective sensor glucose values of a plurality of redundant working electrodes (WEs) of a glucose sensor. Respective electrochemical impedance spectroscopy (EIS) procedures may be performed for each of the WEs to obtain values of membrane resistance (Rmem) for each WE. A noise value and a calibration factor (CF) value may be calculated for each WE, and respective fusion weights may be calculated for Rmem, noise, and CF for each WE. An overall fusion weight may then be calculated based on the WE's Rmem fusion weight, noise fusion weight, and CF fusion weight, such that a single, optimal, fused sensor glucose value may be calculated based on the respective overall fusion weight and sensor glucose value of each of the plurality of redundant working electrodes.

Abstract: The invention relates to protein nanocapsules that exhibit material properties that change in different in vivo environments. A zwitterion moiety on the surface of the nanocapsule can protect the protein from opsonization in a first environment, yet uncouples from the protein nanocapsule in a second environment (e.g. at a pH of less than 6.5). In embodiments of the invention, the uncoupled protein nanocarrier is then internalized by mammalian cells (e.g. tumor cells).

Abstract: An example electrolyte includes a solvent, a lithium salt, and an additive selected from the group consisting of a mercaptosilane, a mercaptosiloxane, and combinations thereof. The electrolyte may be used in a method for making a solid electrolyte interface (SEI) layer on a surface of an electrode. A negative electrode structure may be formed from the method.

Abstract: Disclosed is a tumour therapeutic monoclonal antibody nano-capsule, i.e. a nano-capsule which is prepared by the polymerization of poly 2-methacryloyloxyethyl phosphorylcholine and nimotuzumab, has a round and smooth surface, a uniform particle size and a tumour targeting delivery effect. It has inhibitory effect on proliferation of a tumour, in particular glioma and gastric tumours. The preparation method is taking 0.1-100 mg nimotuzumab solution, adding a monomer having a carbon-carbon double bond, a crosslinker and an initiator respectively according to the molar ratio of the nimotuzumab solution and the monomer having a carbon-carbon double bond, the crosslinker and the initiator of 1:100-1:100000, 1:100-1:10000, 1:100-1:10000 and obtaining the desired product by the method of in situ polymerization.

Abstract: The invention relates to a method for fabricating a regenerative polysulfide-scavenging layer (RSL). The method includes embedding nanowires or nanocrystals of metal oxides with a membrane of carbon nanotubes (CNTs); and forming the RSL with the embedded nanowires or nanocrystals of the metal oxides and the membrane, so as to enable lithium-sulfur batteries with high energy density and prolonged cycling life. The invention also relates to a lithium-sulfur battery that contains the RSL.

Abstract: Alcohol intoxication causes serious diseases, whereas current treatments are mostly supportive and unable to remove alcohol efficiently. Upon alcohol consumption, alcohol is sequentially oxidized to acetaldehyde and acetate by the endogenous alcohol dehydrogenase and aldehyde dehydrogenase, respectively. We disclose a hepatocyte-mimicking antidote for alcohol intoxication through the co-delivery of the nanocapsules of alcohol oxidase (AOx), catalase (CAT), and aldehyde dehydrogenase (ALDH) to the liver, where AOx and CAT catalyze the oxidation of alcohol to acetaldehyde, while ALDH catalyzes the oxidation of acetaldehyde to acetate. Administered to alcohol-intoxicated mice, the antidote rapidly accumulates in the liver and enables a significant reduction of the blood alcohol concentration. Moreover, blood acetaldehyde concentration is maintained at an extremely low level, significantly contributing to liver protection.

Abstract: Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications.

Abstract: Growth factors are of great potential in regenerative medicine. However, their clinical applications are largely limited in by short in vivo half-lives and a narrow therapeutic window. Thus, a robust controlled release system remains an unmet medical need for growth-factor-based therapies. A nanoscale controlled release system (degradable protein nanocapsule) is provided via in-situ polymerization on growth factor. The release rate can be finely tuned by engineering the surface polymer composition. Improved therapeutic outcomes are achieved with the growth factor nanocapsules, as illustrated in spinal cord fusion mediated by bone morphogenetic protein-2 (BMP-2) nanocapsules.

Abstract: The invention relates to methods and materials for extending a circulating half-life of a protein. The method comprises conjugating a protein with a polymerizable acryloyl group and encapsulating the protein with a layer of poly(2-methacryloxyloxyethyl phosphorycholine) (pMPC). The layer of pMPC comprises a plurality of 2-methacryloxyloxyethyl phosphorycholine monomers (MPC) polymerized with a N,N?-methylenebisacrylamide (BIS) crosslinker.

Abstract: The invention provides a general type of porous coordination solids, metal-organic frameworks (MOFs), as an electrode additive to improve thermal stability, rate and cycle performances of batteries, and an electrode having the electrode additive. The incorporation of the MOF additive into the electrode is fully compatible with current battery manufacturing process. Activated MOF additive serves as an electrolyte modulator to enhance cationic transport and alleviates interfacial resistance by interacting liquid electrolyte with unsaturated open metal sites. Moreover, the flow-free liquid in solid configuration is realized by encapsulating liquid electrolyte into porous scaffold of MOF, which offers superior thermal stability.